Advertisement

Topics

Patient Death Triggers FDA Hold For Cellectis’s “Off the Shelf” CAR-T

07:50 EDT 5 Sep 2017 | Xconomy

The FDA has forced Cellectis to shut down two Phase 1 trials it has been running to test an “off the shelf” type of cell therapy—a stinging setback to the France- and New York-based company’s aspirations to leapfrog other developers of CAR-T, a type of cancer immunotherapy that the FDA just approved for the first […]

Original Article: Patient Death Triggers FDA Hold For Cellectis’s “Off the Shelf” CAR-T

NEXT ARTICLE

More From BioPortfolio on "Patient Death Triggers FDA Hold For Cellectis’s “Off the Shelf” CAR-T"

Quick Search
Advertisement
 

Relevant Topic

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...